SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (1213)8/18/1997 9:53:00 PM
From: Pseudo Biologist   of 1762
 
Rick, in reviewing the last few posts I realized I never commented on one of your main points

In any event, it's clear that C2B8 plus CHOP could never finish in time to hurt the launch of Bexxar (relapsed, low-grade). What I'm asking is....... *if* CHOP plus C2B8 led to the occasional cure and *if* patients are sensitized to variable region framework determinants, wouldn't Coulter be in eventual trouble? The same logic would hold for the yttrium conjugate.

Yes, under those assumptions, Bexxar as a treatment for relapsed patients would see a much reduced potential patient population, and yes, the same (even more so, in the light of the V/C region discussion) would apply to Y2B8.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News